Effects of the κ-opioid dynorphin A(1-13) on learning and memory in mice

Behavioural Brain Research

Volumn 83, Issue 1-2, 1997, Pages 169-172

  Ukai, Makoto ^a   Itoh, Jiro ^a   Kobayashi, Tetsuya ^a   Shinkai, Norihiro ^a   Kameyama, Tsutomu ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

dynorphin A(1 13); mouse; passive avoidance response; pirenzepine; scopolamine; spontaneous alternation performance; opioid receptor

Indexed keywords

DYNORPHIN[1-13]; KAPPA OPIATE RECEPTOR ANTAGONIST; MUSCARINIC M1 RECEPTOR; NORBINALTORPHIMINE; PIRENZEPINE; SCOPOLAMINE;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LEARNING; MALE; MEMORY; NONHUMAN; PRIORITY JOURNAL;

EID: 0031081066     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(97)86063-9     Document Type: Conference Paper

References (25)

1. [1] Caulfield, M.P.C., Higgins, G.A. and Straughan, D.W., Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectivity impairs passive avoidance learning in the mouse, J. Pharm. Pharmacol., 24 (1983) 131-132.
2. [2] Davies, P. and Maloney, A.J.F., Selective loss of central cholinergic neurons in Alzheimer's disease, Lancet, 2 (1976) 1403.
3. [3] Davis, K.L. and Yamamura, H.I., Cholinergic underactivity in human memory disorders, Life Sci., 23 (1978) 1729-1734.
4. [4] Del Cerro, S. and Borrell, J., Dynorphin 1-17 can enhance or impair retention of an inhibitory avoidance response in rats, Life Sci., 47 (1990) 1453-1462.
5. [5] Drachman, D.A., Memory and cognitive function in man: does the cholinergic system have a specific role?, Neurology, 27 (1977) 783-790.
6. [6] Hagan, J.J., Jansen, J.H.M. and Broekkamp, C.L.E., Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine, Psychopharmacology, 93 (1987) 470-476.
7. [7] Haley, T.J. and McCormick, W.G., Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse, Br. J. Pharmacol., 12 (1957) 12-15.
8. [8] Hiller, J.M., Itzak, Y. and Simon, E.J., Selective changes in μ, δ and κ opioid receptor binding in certain limbic regions of the brain in Alzheimer's disease patients, Brain Res., 106 (1987) 17-23.
9. [9] Hunter, A.J. and Roberts, F.F., The effect of pirenzepine on spatial learning in the Morris water maze, Pharmacol. Biochem. Behav., 30 (1988) 519-523.
10. [10] Itoh, J., Ukai, M. and Kameyama, T., Dopaminergic involvement in the improving effects of dynorphin A-(1-13) on scopolamine-induced impairment of alternation performance, Eur. J. Pharmacol., 241 (1993) 99-104.
11. [11] Itoh, J., Ukai, M. and Kameyama, T., U-50,488H, a κ-opioid receptor agonist, markedly prevents memory dysfunctions induced by transient cerebral ischemia in mice, Eur. J. Pharmacol., 619 (1993) 223-228.
12. [12] Izquierdo, I., De Almeida, M.A.M.R. and Emiliano, V.R., Unlike β-endorphin, dynorphin 1-13 does not cause retrograde amnesia for shuttle avoidance or inhibitory avoidance learning in rats, Psychopharmacology, 87 (1985) 216-218.
13. [13] Lapchak, P.A., Araujo, D.M. and Collier, B., Regulation of endogenous acetylcholine release from mammalian brain slices by opiate receptors: hippocampus, striatum and cerebral cortex of guinea pig and rat, Neuroscience, 31 (1989) 313-325.
14. [14] Levey, A.I., Kitt, C.A., Simonds, W.F., Price, D.L. and Brann, M.R., Identification and localization of muscarinic acetylcholine receptor protein in brain with subtype-specific antibodies, J. Neurosci., 11 (1991) 3218-3226.
15. [15] McDaniel, K.W., Mundy, W. and Tilson, H.A., Microinjection of dynorphin into the hippocampus impairs spatial learning in rats, Pharmacol. Biochem. Behav., 35 (1990) 429-432.
16. [16] McGurk, S.R., Levin, E.D. and Butcher, L.L., Cholinergic-dopaminergic interactions in radial-arm maze performance, Behav. Neural Biol., 49 (1988) 234-238.
17. [17] Ofri, D., Fan, L., Simon, E.J. and Hiller, J.M., Lesioning of the nucleus basalis of Meynert has differential effects on mu, delta and kappa opioid receptor binding in rat brain: a quantitative autoradiographic study, Brain Res., 581 (1992) 252-260.
18. [18] Perry, E.K., Perry, R.H., Blessed, G. and Tomlinson, B.E., Necropsy evidence of central cholinergic deficits in senile dementia, Lancet, 1 (1977) 189.
19. [19] Reid, M., Herrera-Marschitz, M., Hökfelt, T., Terenius, L. and Ungerstedt, U., Differential modulation of striatal dopamine release by intranigral injection of γ-aminobutyric acid (GABA), dynorphin A and substance P, Eur. J. Pharmacol., 147 (1988) 411-420.
20. [20] Sala, M.D., Braida, P., Calcaterra, M.P., Leone, F.A., Comotti, S., Gianola and Gori, E. Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat, Eur. J. Pharmacol., 194 (1991) 45-46.
21. [21] Sarter, M., Bodewitz, G. and Stephens, D., Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist β-carbolines, Psychopharmacology, 94 (1988) 491-495.
22. [22] Sen, A.P. and Bhattacharya, S.K., Effect of selective muscarinic receptor agonists and antagonists on active-avoidance learning acquisition in rats, Indian J. Exp. Biol., 29 (1991) 136-139.
23. [23] Ukai, M., Kobayashi, T. and Kameyama, T., Dynorphin A-(1-13) attenuates basal forebrain-lesion-induced amnesia in rats, Brain Res., 625 (1993) 355-356.
24. [24] Wall, S.J., Yasuda, R.P., Hory, F., Flagg, S., Martin, B.M., Ginns, E.I. and Wolfe, B.B., Production of antisera selective for m1 muscarinic receptors using fusion proteins: distribution of m1 receptors in rat brain, Mol. Pharmacol., 39 (1991) 643-649.
25. [25] White, P., Hiley, C.R., Goodhardt, M.J., Carrasco, L.H., Keet, J.P. and Williams, I.E.I., Neocortical cholinergic neurons in elderly people, Lancet, 1 (1977) 668-671.